Xenon Pharmaceuticals Inc
XENE44.840USD
-0.170-0.38%
終値 12/26, 16:00（ET）15分遅れの株価
3.46B時価総額
損失額直近12ヶ月PER
詳細情報 Xenon Pharmaceuticals Inc 企業名
Xenon Pharmaceuticals Inc. is a Canada-based neuroscience-focused biopharmaceutical company committed to discovering, developing, and commercializing therapeutics to improve the lives of people living with neurological and psychiatric disorders. The Company is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, a novel, highly potent, selective Kv7 potassium channel opener, represents the advanced, clinically validated potassium channel modulator in late-stage clinical development for the treatment of multiple indications that include epilepsy, including focal onset seizures (FOS), and primary generalized tonic-clonic seizures (PGTCS), as well as neuropsychiatric disorders including major depressive disorder (MDD), and bipolar depression (BPD). The Company is evaluating multiple therapeutic candidates targeting Kv7, Nav1.7, and Nav1.1 across various indications.
Xenon Pharmaceuticals Incの企業情報
企業コードXENE
会社名Xenon Pharmaceuticals Inc
上場日Oct 17, 2014
最高経営責任者「CEO」Mortimer (Ian C)
従業員数316
証券種類Ordinary Share
決算期末Oct 17
本社所在地3650 Gilmore Way
都市VANCOUVER
証券取引所NASDAQ OMX - NASDAQ BASIC
国Canada
郵便番号V5G 4W8
電話番号16044843300
ウェブサイトhttps://www.xenon-pharma.com/
企業コードXENE
上場日Oct 17, 2014
最高経営責任者「CEO」Mortimer (Ian C)
Xenon Pharmaceuticals Incの経営陣
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Gary Patou, M.D.
Dr. Gary Patou, M.D.
Independent Director
Independent Director
28.48K
--
Ms. Dawn A. (Graham) Svoronos
Ms. Dawn A. (Graham) Svoronos
Lead Independent Chairman of the Board
Lead Independent Chairman of the Board
25.00K
--
Mr. Ian C. Mortimer, CPA
Mr. Ian C. Mortimer, CPA
President, Chief Executive Officer, Principal Operating Officer, Director
President, Chief Executive Officer, Principal Operating Officer, Director
20.30K
-55.39%
Mr. Steven R. (Steve) Gannon, CPA
Mr. Steven R. (Steve) Gannon, CPA
Independent Director
Independent Director
7.14K
-0.04%
Mr. Thomas J. (Tucker) Kelly, J.D.
Mr. Thomas J. (Tucker) Kelly, J.D.
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Christopher Kenney, M.D.
Dr. Christopher Kenney, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Darren S. Cline
Mr. Darren S. Cline
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. Patrick Machado, J.D.
Mr. Patrick Machado, J.D.
Independent Director
Independent Director
--
--
Dr. Gillian M. Cannon, Ph.D.
Dr. Gillian M. Cannon, Ph.D.
Independent Director
Independent Director
--
--
Mr. Justin Gover
Mr. Justin Gover
Independent Director
Independent Director
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Gary Patou, M.D.
Dr. Gary Patou, M.D.
Independent Director
Independent Director
28.48K
--
Ms. Dawn A. (Graham) Svoronos
Ms. Dawn A. (Graham) Svoronos
Lead Independent Chairman of the Board
Lead Independent Chairman of the Board
25.00K
--
Mr. Ian C. Mortimer, CPA
Mr. Ian C. Mortimer, CPA
President, Chief Executive Officer, Principal Operating Officer, Director
President, Chief Executive Officer, Principal Operating Officer, Director
20.30K
-55.39%
Mr. Steven R. (Steve) Gannon, CPA
Mr. Steven R. (Steve) Gannon, CPA
Independent Director
Independent Director
7.14K
-0.04%
Mr. Thomas J. (Tucker) Kelly, J.D.
Mr. Thomas J. (Tucker) Kelly, J.D.
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Christopher Kenney, M.D.
Dr. Christopher Kenney, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
収益内訳
FY2025Q2
FY2025Q1
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
会社から関連データがまだ開示されていません。
地域別USD
会社名
収益
比率
Canada
0.00
0.00%
事業別
地域別
会社から関連データがまだ開示されていません。
株主
更新時刻: Sun, Nov 16
更新時刻: Sun, Nov 16
株主統計
種類
株主統計
株主統計
比率
Fidelity Management & Research Company LLC
8.09%
Avoro Capital Advisors LLC
6.99%
Driehaus Capital Management, LLC
5.40%
BlackRock Institutional Trust Company, N.A.
5.25%
Janus Henderson Investors
5.10%
他の
69.17%
株主統計
株主統計
比率
Fidelity Management & Research Company LLC
8.09%
Avoro Capital Advisors LLC
6.99%
Driehaus Capital Management, LLC
5.40%
BlackRock Institutional Trust Company, N.A.
5.25%
Janus Henderson Investors
5.10%
他の
69.17%
種類
株主統計
比率
Investment Advisor/Hedge Fund
48.11%
Investment Advisor
33.86%
Hedge Fund
25.98%
Research Firm
1.49%
Private Equity
1.01%
Sovereign Wealth Fund
0.82%
Pension Fund
0.75%
Bank and Trust
0.40%
Individual Investor
0.11%
機関投資家保有株
更新時刻: Wed, Oct 1
更新時刻: Wed, Oct 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q3
446
85.67M
110.86%
-494.45K
2025Q2
418
85.39M
111.27%
+856.94K
2025Q1
434
79.94M
104.19%
-5.23M
2024Q4
434
79.81M
104.31%
-4.80M
2024Q3
425
77.49M
102.39%
-3.82M
2024Q2
431
76.92M
102.03%
-4.12M
2024Q1
421
76.68M
101.81%
-2.76M
2023Q4
404
75.13M
102.42%
+7.65M
2023Q3
386
64.60M
99.41%
-3.93M
2023Q2
377
64.25M
101.09%
-4.03M
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
Fidelity Management & Research Company LLC
6.40M
8.3%
+244.00K
+3.96%
Jun 30, 2025
Avoro Capital Advisors LLC
5.40M
7%
-341.67K
-5.95%
Jun 30, 2025
Driehaus Capital Management, LLC
4.34M
5.62%
-249.21K
-5.44%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
4.12M
5.34%
+3.47M
+534.85%
Jun 30, 2025
Janus Henderson Investors
3.58M
4.64%
+252.64K
+7.60%
Jun 30, 2025
Wellington Management Company, LLP
2.17M
2.82%
-1.61M
-42.61%
Jun 30, 2025
Braidwell LP
3.61M
4.68%
+895.15K
+33.03%
Jun 30, 2025
Capital International Investors
3.18M
4.13%
+92.82K
+3.01%
Jun 30, 2025
Commodore Capital LP
3.02M
3.92%
+700.00K
+30.11%
Jun 30, 2025
Fidelity Institutional Asset Management
2.48M
3.22%
+352.87K
+16.57%
Jun 30, 2025
詳細を見る
関連ETF
更新時刻: Sat, Dec 6
更新時刻: Sat, Dec 6
銘柄名
比率
iShares Neuroscience and Healthcare ETF
4.41%
ALPS Medical Breakthroughs ETF
1.35%
Goldman Sachs Future Health Care Equity ETF
1.13%
Virtus LifeSci Biotech Clinical Trials ETF
0.87%
First Trust Multi-Manager Small Cap Opportunities ETF
0.8%
JPMorgan Fundamental Data Science Small Core ETF
0.57%
JPMorgan Healthcare Leaders ETF
0.53%
iShares MSCI USA Small-Cap Min Vol Factor ETF
0.45%
ProShares Ultra Nasdaq Biotechnology
0.42%
Invesco Nasdaq Biotechnology ETF
0.32%
詳細を見る
iShares Neuroscience and Healthcare ETF
比率4.41%
ALPS Medical Breakthroughs ETF
比率1.35%
Goldman Sachs Future Health Care Equity ETF
比率1.13%
Virtus LifeSci Biotech Clinical Trials ETF
比率0.87%
First Trust Multi-Manager Small Cap Opportunities ETF
比率0.8%
JPMorgan Fundamental Data Science Small Core ETF
比率0.57%
JPMorgan Healthcare Leaders ETF
比率0.53%
iShares MSCI USA Small-Cap Min Vol Factor ETF
比率0.45%
ProShares Ultra Nasdaq Biotechnology
比率0.42%
Invesco Nasdaq Biotechnology ETF
比率0.32%
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
種類
比率
データなし
日付
種類
比率
データなし
よくある質問
Xenon Pharmaceuticals Incの上位5名の株主は誰ですか？
Xenon Pharmaceuticals Incの上位5名の株主は以下のとおりです。
Fidelity Management & Research Company LLCは6.40M株を保有しており、これは全体の8.30%に相当します。
Avoro Capital Advisors LLCは5.40M株を保有しており、これは全体の7.00%に相当します。
Driehaus Capital Management, LLCは4.34M株を保有しており、これは全体の5.62%に相当します。
BlackRock Institutional Trust Company, N.A.は4.12M株を保有しており、これは全体の5.34%に相当します。
Janus Henderson Investorsは3.58M株を保有しており、これは全体の4.64%に相当します。
Fidelity Management & Research Company LLCは6.40M株を保有しており、これは全体の8.30%に相当します。
Avoro Capital Advisors LLCは5.40M株を保有しており、これは全体の7.00%に相当します。
Driehaus Capital Management, LLCは4.34M株を保有しており、これは全体の5.62%に相当します。
BlackRock Institutional Trust Company, N.A.は4.12M株を保有しており、これは全体の5.34%に相当します。
Janus Henderson Investorsは3.58M株を保有しており、これは全体の4.64%に相当します。
Xenon Pharmaceuticals Incの株主タイプ上位3種は何ですか？
Xenon Pharmaceuticals Incの株主タイプ上位3種は、
Fidelity Management & Research Company LLC
Avoro Capital Advisors LLC
Driehaus Capital Management, LLC
Fidelity Management & Research Company LLC
Avoro Capital Advisors LLC
Driehaus Capital Management, LLC
Xenon Pharmaceuticals Inc（XENE）の株式を保有している機関の数はいくつですか？
2025Q3時点で、Xenon Pharmaceuticals Incの株式を保有している機関は446社あり、保有株式の総市場価値は約85.67Mで、全体の110.86%を占めています。2025Q2と比較して、機関の持ち株は-0.41%増加しています。
Xenon Pharmaceuticals Incの最大の収益源は何ですか？
FY2025Q2において、--部門がXenon Pharmaceuticals Incにとって最大の収益を生み出しており、その金額は--で、全収益の--%を占めています。
